Endocare — C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference 2005
20 slides from Endocare's conference presentation, Oct 21, 2005
Slide 1: Endocare, Inc. at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
Endocare, Inc. C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference October 25, 2005
Slide 2: Forward-Looking Statements
Forward-Looking Statements, etc. Statements contained in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements
Slide 3: Topics
Topics: Our Vision Statement Technology & Products Current Performance & Financials Preview 2006
Slide 4: Vision
Vision Endocare is a medical device manufacturer focused on improving the health and quality of patients' lives through safe, cost effective, proprietary cryoablation technologies for treating cancerous tissue and tumors, and vacuum therapy for the treatment of erectile dysfunction.
Slide 5: Company Highlights
Company Highlights Historical procedure growth 33%+ per year Current market penetration is less than 3% Proven and experienced management team Clinically proven technology in prostate cancer Strong IP positioning and patent protection $400 million growing market in prostate cancer $750 million growi
Slide 6: Endocare Technology Groups
Endocare Technology Groups Vacuum Technology Erectile Dysfunction Cryoablation Technology Urology Renal Cancer Prostate Cancer Radiology Liver Tumors Lung Tumors Bone Pain
Slide 7: Current Cryo Systems (The Razor)
TM Current Cryo Systems (The "Razor") CryoCare CryoCare TM
Slide 8: CryoProbe (Razor Blades)
CryoProbe (Razor Blades) Urology Interventional Radiology Features Multiple Probe System Right Angle design CT-compatible Fits under CT Gantry Tumors easily targeted Wide grip handle Features 6 - 2.4 mm CryoProbes 6 - TemProbes Warming Catheter CryoGrid
Slide 9: Urology - Primary Prostate Cancer Population
Urology - Primary Prostate Cancer Population 2004 Number of Primary Cryotherapy Procedures 5000 Estimated # of All Other Treatments 212000 Source: Health Advances Interviews, Millennium Research Group, CJS Securities and Company estimates. ACS - 2004 Prostate Cancer Diagnosis Estimates Potential Pri
Slide 10: Industry-wide Procedures per Year - Kidney, Liver, Lung & Bone Pain
0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 2002 2003 2004 2005 2006 2007 2008 2009 2010 Procedures per Year Kidney Procedures Liver Procedures Bone Procedures Lung Procedures Interventional Radiology & Oncology Industry-wide Procedures per Year - Kidney, Liver, Lung & Bone Pain
Slide 11: Urology Business and Interventional Radiology Business
Urology Business Emerging Growth Clinical Results - Equivalent 10-Year Data Reimbursement Established Community Physician Focus Education & Behavior Change Patient Consumer Early Stage Clinical Results "Proving" Reimbursement Enhanced or Established Academic Center Focus Clinical Demonstration Inter
Slide 12: Endocare Procedure Growth
Endocare Procedure Growth 1,546 3,554 2,479 Endocare Direct Market Procedure Growth Reflects all Cryo Procedures Completed 2001 - First Half 2005 2001-2004 Actual and 1st Six Months 2005 4,720 6,550 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 2001 2002 2003 2004 6 Months 2005 3,106
Slide 13: Quarterly Procedure Growth
% Inc OPYQ 62% 90% 44% 47% 26% 27% 50% 60% 48% 55% 17% 25% 41% 25% Q3 2005 1,600+ Projected
Slide 14: Summary Annual Financial Data
Summary Annual Financial Data
Slide 15: Summary Quarterly Financial Data
Summary Quarterly Financial Data * 3rd Quarter 2005 Results Not Yet Reported ($000's) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Total revenues 7,382 $ 8,312 $ 8,365 $ 8,626 $ 9,126 $ 9,078 $ * Gross margin % 42.6% 48.1% 48.9% 52.5% 44.5% 49.5% * SG&A expenses 11,179 $ 9,089 $ 6,994 $ 7,699 $ 8,288 $ 7,828 $ * Less Than
Slide 16: Additional & Potential Cash Use
Additional & Potential Cash Use Q3 2005 S-2 Liquidated Damages $500,000 D&O Carrier Arbitration Settlement $1,000,000 SEC Settlement $750,000 Delinquent State & Local Taxes (Pre-2004) $975,000 Investigation Related Legal Fees $100,000
Slide 17: Why Endocare?
Clinically proven technology for tissue and tumor ablation. Strong IP and broad market potential. Rapid procedural growth in large expanding markets. Accelerating market acceptance among physicians, academics, patients and payors. Gross margins, net income and operating results are expected to impro
Slide 18: Endocare Comparable Companies Analysis
Endocare Comparable Companies Analysis - Market and Trading Data ($ in millions)
Slide 19: 2006 Outlook & Assessment
2006 Outlook & Assessment The issues should be behind us SEC, DOJ... and National Listing occurs Management can focus on Achievement Milestones to Track & Assess: Procedural growth - 35%+ annually Improving gross margins Declining use of cash Potential to expand to new markets
Slide 20: Thank you for your Interest & Consideration
Thank you for your Interest & Consideration
Endocare — C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference 2005 on 6ix